Peak Pharmaceuticals (OTCMKTS:PKPH) and Inventiva (NASDAQ:IVA) Financial Survey

Inventiva (NASDAQ:IVA) and Peak Pharmaceuticals (OTCMKTS:PKPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

19.1% of Inventiva shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 18.4% of Peak Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Inventiva and Peak Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Peak Pharmaceuticals	N/A	N/A	-159.55%

Volatility & Risk

Inventiva has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Peak Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Inventiva and Peak Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	0	0	7	0	3.00
Peak Pharmaceuticals	0	0	0	0	N/A

Inventiva presently has a consensus target price of $17.00, indicating a potential upside of 655.56%. Given Inventiva’s higher possible upside, research analysts plainly believe Inventiva is more favorable than Peak Pharmaceuticals.

Earnings & Valuation

This table compares Inventiva and Peak Pharmaceuticals’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$17.48 million	6.76	-$119.51 million	N/A	N/A
Peak Pharmaceuticals	N/A	N/A	-$160,000.00	N/A	N/A

Peak Pharmaceuticals has lower revenue, but higher earnings than Inventiva.

Summary

Inventiva beats Peak Pharmaceuticals on 7 of the 8 factors compared between the two stocks.

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

About Peak Pharmaceuticals

Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Scottsdale, AZ.